NCT07781436Not yet recruiting
A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG
Randomized Controlled Trial of Fuzheng Yangxin Formula in Enhanced Recovery After Coronary Artery Bypass Grafting
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
This study aims to evaluate the efficacy and safety of Fuzheng Yangxin Formula (FZYXF) in the treatment of qi-yin deficiency syndrome after coronary artery bypass grafting (CABG), formulate an integrated Chinese and Western medicine rehabilitation protocol, develop special proprietary Chinese medicines for postoperative patients, establish a postoperative rehabilitation database, and promote the standardized application and achievement transformation of integrated Chinese and Western medicine therapy in cardiac surgery.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- First submitted
- 4 Aug 2026
- Start date
- 10 Aug 2026
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- Peking University Third Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07781436
What you commit to
- Study type: Interventional
- Planned participants: 230
- From 10 Aug 2026 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with fever or common cold after surgery.
- Patients who receive concurrent valve surgery or other intracardiac operations
Other illness
- Patients with hypersensitivity to any components of Fuzheng Yangxin Formula granules.
- Patients with end-stage malignant tumors
- Patients with uncontrolled infection or bleeding
- Patients with progressive degenerative systemic diseases, such as severe trauma, multiple organ failure and other severe impairment of vital organ function including severely damaged liver function
- Patients with severe heart failure or cardiogenic shock who cannot tolerate treatment.
Other
- Patients with severe postoperative liver and kidney dysfunction.
Who the study is looking for
- -Patients who have undergone coronary artery bypass grafting (CABG) and present with postoperative qi-yin deficiency syndrome.
Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University 3rd Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.